Methotrexate-albumin and aminopterin-albumin effectively prevent experimental acute graft-versus-host disease

Transplantation

Volumn 82, Issue 4, 2006, Pages 527-533

  Wolff, Daniel ^a   Frei, Eva ^b   Hofmeister, Nicole ^a   Steiner, Beate ^a   Kleine, Hans Dieter ^a   Junghanss, Christian ^a   Sievert, Kathrin ^a   Terpe, Harald ^a   Schrenk, Hans Hermann ^b   Freund, Mathias ^a   Hartung, Gernot ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Allogeneic stem cell transplantation; Aminopterin albumin; Graft versus host disease; Human serum albumin; Methotrexate albumin

Indexed keywords

AMINOPTERIN ALBUMIN CONJUGATE; CYTOTOXIC AGENT; METHOTREXATE ALBUMIN CONJUGATE; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; FEMALE; GAMMA IRRADIATION; LETHARGY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SPLEEN CELL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; T LYMPHOCYTE; WEIGHT REDUCTION;

ACUTE DISEASE; AMINOPTERIN; ANIMALS; FEMALE; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; METHOTREXATE; RATS; RATS, INBRED LEW; SERUM ALBUMIN;

EID: 33747889199     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000229451.40286.64     Document Type: Article

References (32)

1. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702.
2. Horowitz MM. Uses and Growth of Hematopoietic Cell Transplantation. In: Thomas ED BKFSe, ed. Hematopoietic Stem Cell Transplantation. Boston: Blackwell Science, 1999: 12.
3. Storb R, Pepe M, Deeg HJ, et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992; 80: 560.
4. Ringden O, Klaesson S, Sundberg B, et al. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992; 9: 19.
5. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729.
6. Huffmann D, Wan S, Azarnoff D, Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973; 14: 572.
7. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621.
8. Hartung G, Stehle G, Sinn H, et al. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Clin Cancer Res 1999; 5: 753.
9. Vis N, van der GA, van Rhijn G, et al. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 2002; 49: 342.
10. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997; 26: 77.
11. Wunder A, Muller-Ladner U, Stelzer EH, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003; 170: 4793.
12. Fiehn C, Muller-Ladner U, Gay S, et al. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford) 2004; 43: 1097.
13. Weigand M, Hartung G, Roboz J, et al. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone. Anticancer Drug Des 2001; 16: 227.
14. Wosikowski K, Biedermann E, Rattel B, et al. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells. Clin Cancer Res 2003; 9: 1917.
15. Stehle G, Sinn H, Wunder A, et al. The loading rate determines tumor targeting properties of methotrexate- albumin conjugates in rats. Anticancer Drugs 1997; 8: 677.
16. Stehle G, Wunder A, Sinn H, et al. Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer Drugs 1997; 8: 835.
17. Burger AM, Hartung G, Stehle G, et al. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 2001; 92: 718.
18. Stehle G, Wunder A, Schrenk HH, et al. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats. Anticancer Drugs 1999; 10: 405.
19. Wunder A, Stehle G, Schrenk HH, et al. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer 1998; 76: 884.
20. Fiehn C, Neumann E, Wunder A, et al. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann Rheum Dis 2004; 63: 884.
21. Xystrakis E, Bernard I, Dejean AS, et al. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset. Eur J Immunol 2004; 34: 408.
22. Farber S. Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA 1966; 198: 826.
23. Ratliff AF, Wilson J, Hum M, et al. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 1998; 16: 1458.
24. Eschen N, Bauder-Wust U, Frei E, et al. Aminopterin-human serum albumin conjugate (AP-HSA): uptake and cytotoxic effects in tumor cell lines. Int J Clin Pharmacol Ther 2002; 40: 564.
25. Kremer P, Hartung G, Bauder-Wust U, et al. Efficacy and tolerability of an aminopterin-albumin conjugate in tumor- bearing rats. Anticancer Drugs 2002; 13: 615.
26. Stehle G, Wunder A, Schrenk HH, et al. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate. Anticancer Drugs 1999; 10: 785.
27. Kleine HD, Zech I, Nowak R, et al. Detection of residual aneuploid leukemic cells by "continuous gating." Cytometry 1999; 36: 71.
28. Kremer P, Wunder A, Sinn H, et al. Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results. Neurol Res 2000; 22: 481.
29. Cutolo M, Bisso A, Sulli A, et al. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J Rheumatol 2000; 27: 2551.
30. Durez P, Appelboom T, Vray B, et al. Methotrexate inhibits LPS-induced tumor necrosis factor production in vivo. Eur Cytokine Netw 1998; 9: 669.
31. Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35: 1089.
32. Wunder A, Stehle G, Sinn H et al. Antitumor activity of MTX-HSA conjugates in rats. Eur J Cancer 1997; 33: 178.